The Latest News From OB Pharmaceuticals

TORONTO, ONTARIO – December 4, 2020 – OB Pharmaceuticals, Inc., announced today the company will present its poster on its lead molecule, TD567 in preclinical studies of its effects on seizures resulting from traumatic brain injury (TBI) at the American Epilepsy Society Annual Meeting being held virtually from December 4 through December 8.  "TD567 continues to demonstrate great potential as a lead molecule, not only for its efficacy for these often intractable seizures but also for its excellent profile as a drug candidate", said Dr. Larry Mahan, CEO.  Data will be presented for 3 different preclinical TBI models comparing TD567 against standard of care antiepileptic drugs.

The details for the poster presentation are as follows and are available online at AES 2020 for review.

Abstract No. 850: TD567, A Novel Carboxyphenolcyclohexenone as a Drug Candidate for the Treatment of Post-traumatic Epilepsy

LONDON, ONTARIO June 12, 2020 -- OB Pharmaceuticals announces the appointment of Dr. Michael Rogawski to Chief Scientific Advisor and Chair of its Scientific and Clinical Advisory Board. Dr. Rogawski, a professor of neurology and pharmacology at the University of California, Davis School of Medicine, is an internationally recognized expert on antiseizure medications and drug discovery and development for epilepsy. He teaches in the UC Davis School of Medicine, is on the active medical staff of UC Davis Health, and was formerly chair of the Neurology Department there.

“I am delighted to assist OB Pharmaceuticals in bringing transformational therapies for epilepsy to patients,” said Dr. Rogawski. “OB has a unique discovery platform that has successfully identified a differentiated class of molecules with the potential to prevent seizures in individuals suffering from epilepsy who are resistant to current treatments.”

Before UC Davis, Dr. Rogawski was senior investigator and chief of the Epilepsy Research Section at the National Institute of Neurological Disorders and Stroke (NIH-NINDS).

"Having known Mike back from our days at NIH together, I am confident he will provide the level of guidance going forward to ensure our success as we move TD567 through late preclinical and into the regulatory process and clinical development," remarked Dr. Larry Mahan, CEO. "I look forward to working closely with him."

Dr. Rogawski graduated from Amherst College with a B.A. in biophysics and from Yale University with an M.D. and Ph.D. in pharmacology. After serving as a postdoctoral fellow in the Laboratory of Neurophysiology, NINDS, he completed residency training in neurology at Johns Hopkins. He has served on the board of directors of the American Epilepsy Society and as an advisor to the NIH and the Food and Drug Administration in the U.S.

“We are pleased and excited to welcome Mike into an expanded role with the company. He brings an uncommon combination of high-level scientific and clinical expertise along with advanced corporate development abilities” commented John Poulter, Chairman. “He is well versed in our science and will strongly complement the expertise of Larry Mahan, our CEO, in filling the role left vacant with last year’s passing of my brother and co-founder Mike.”

LONDON, ONTARIO June 12, 2020 -- OB Pharmaceuticals has been granted patent US 10,618,870 from the U.S. Patent and Trademark Office (USPTO) for its first family of new chemical entities (NCEs) relating to compounds and pharmaceutical compositions for reducing the severity of convulsant activity, or epileptic seizures. In addition, these compounds have shown initial effectiveness in preclinical models of pain as covered in the original filing.

Additionally, the company was recently granted another patent US 10,556,853 for its second chemical family of compounds for utility as a method for reducing the severity of convulsant activity for one set of its structural classes. The second structural class is under review currently for the same, and requisite continuations and divisionals have been filed for pharmaceutical composition. Based on a prior “green light” PCT examination outcome of this second patent family, we believe the U.S. allowances will be forthcoming.

Both patent families have entered national phase reviews globally.

LONDON, ONTARIO June 12, 2020 -- Dr. Larry Mahan, CEO of OB Pharmaceuticals, attended the
Biotechnology Innovation Organization’s International Convention (June 8-12) in its Digital BIO 2020
format to meet with prospective investors for the company's capital raise initiative and with key
contract research organizations whose services will be required moving forward. The company is
concluding its preclinical lead development phase for TD567 and will be seeking funding to complete
IND/CTA-enabling GLP toxicology studies prior to filing its IND and CTA to proceed into clinical trials.
These introductory meetings resulted in several follow-on requests by investors.

Dr. Larry Mahan attended the Park City Epilepsy Conference

LONDON, ONTARIO August 20, 2019 -- It is with great sadness that OB Pharmaceutical announces the sudden death of its cofounder and CSO, Dr. Michael Poulter, after a short illness. Dr. Poulter received his undergraduate degree in Pharmacology from the University of British Columbia. He continued his studies at McGill University where he received a PhD in Pharmacology and conducted his postgraduate research at the NIH in Washington DC and at the Université Louis Pasteur, Strasbourg, France. Dr. Poulter returned to Canada in 1995, taking positions first at the National Research Council in Ottawa and subsequently at the Institute for Neuroscience at Carleton University, becoming head of the Institute in 2003. In 2006 he relocated to London, ON, taking a position as Scientist at the Robarts Research Institute and as Professor in the Department of Physiology and Pharmacology at the University of Western Ontario. He dedicated his life to epilepsy research and donated his time to Epilepsy Canada, as a Board Member and a Member of the Scientific Research Committee, with a mission to find a cure and enhance other research efforts across Canada. Moreover, he was an avid skier and advanced sailor, a great bass player and an excellent cook. He cofounded OB Pharmaceuticals with operations starting in the fall of 2014 and led the preclinical program through lead discovery, creating novel in vivo models to elucidate the nature and control of seizures arising from traumatic brain injury. "Mike has been a dear friend and colleague of mine in science and business for 30 years." remarked Dr. Larry Mahan, CEO of OB Pharmaceuticals. "We will honor his memory by intensifying our efforts to bring our compounds into the clinic and ultimately as therapies for those unmet medical needs in patients who suffer these debilitating disorders." The company has initiated steps to fill the CSO position.

LONDON, ONTARIO May 16, 2019 -- OB Pharmaceuticals CSO, Dr. Michael Poulter in the News.

Dr. Michael Poulter, CSO was interviewed for CTV News discussing his latest research investigating the mechanisms of traumatic brain injury (TBI) induced seizures. For the full interview, watch: https://london.ctvnews.ca/new-hope-for-treating-epilepsy-developed-after-traumatic-brain-injury-1.4425431.

READ THE RELEASE

LONDON, ONTARIO January 12, 2019 -- Dr. Larry Mahan, CEO of OB Pharmaceuticals, attended the JP Morgan Healthcare Conference week (Jan. 7-10) in San Francisco, CA to meet with prospective investors for the company's upcoming Series A capital raise initiative and with key pharmaceutical companies in the epilepsy therapeutic market as potential strategic partners moving forward. The company is concluding its preclinical lead development phase for TD567 and will be seeking funding to complete IND/CTA-enabling GLP toxicology studies prior to filing its IND and CTA to proceed into clinical trials. Meetings resulted in a number of follow-on diligence actions by investors and interested pharmaceutical business development representatives.

About J.P. Morgan

The annual J.P. Morgan Healthcare Conference, held each January in San Francisco, CA, brings thousands of investors from around the world together. The hundreds of companies presenting run the gamut, from start-ups to those with more than $300 billion in market cap, and encompass the entire global healthcare landscape, including pharmaceutical firms, healthcare service providers, profit and not-for-profits, and medical device companies.

LONDON, ONTARIO October 2, 2018 -- OB Pharmaceuticals has been granted utility patent US 10,087,138 from the U.S. Patent and Trademark Office (USPTO) for its first family of new chemical entities (NCEs) relating methods for reducing the severity of convulsant activity, or epileptic seizures. In addition, these compounds have shown initial effectiveness in preclinical models of pain as covered in the original filing. A continuation filing for novel composition of matter for this family is in place and awaiting review.

LONDON, ONTARIO May 2, 2018 -- OB Pharmaceuticals was invited to present the details of its drug development program of oxynytones at the 14th Eilat Conference in Madrid, Spain May 13-16, 2018. Dr. Michael Poulter will discuss the unique differentiating properties of these novel compounds and the compelling preclinical evidence in support of their continued development as promising therapeutics for the treatment of epilepsy and other related seizure disorders.

About Eilat XIV
The Eilat Conference on New Antiepileptic Drugs and Devices will take place from 13th May to 16th May 2017 at the Melia Castilla Hotel & Convention Center in Madrid, Spain. The conference will cover areas like designed to provide an in-depth progress report on new antiepileptic drugs in various stages of development, as well as to present new findings on second-generation treatments. For more information: https://www.eilatxiv.com

LONDON, ONTARIO April 2, 2018 -- Chairman and CEO John Poulter announced the appointment of Dr. Larry Mahan as the new CEO of OB Pharmaceuticals (OB). Dr. Mahan served previously on the company's advisory board and later as VP Business Development providing preclinical, clinical and strategic business development direction.

"The Board of Directors is pleased to have Larry increase his role as CEO within OB. Over the past few years Larry’s guidance has been invaluable to the company", remarked John Poulter. "Given his experience in the industry and his detailed knowledge of OB’s operations his evolution to this new role is natural. As the company begins to move its focus from our own labs and onto the stage of Investigative New Drug status it is critical that the company is led by professionals with deep industry experience. The board is unanimous in the belief that Larry’s is well suited to navigate OB toward its next important milestones. It is contemplated that Larry will be invited to sit on OB’s board where I will continue with the role of Chairman."

Dr. Mahan received his PhD in Physiology and Pharmacology from the University of California, San Diego and went on to post-graduate work at the NIH under a prestigious Pharmacology Research Associate Traineeship in the laboratory of Nobel Laureate Dr. Julius Axelrod (NIMH). His 12-year career at NIMH and later NINDS focused on molecular neuropharmacology and the identification and characterization of neurotransmitter receptors using expression cloning technologies. Following, he cofounded TherExcell, Inc. with Dr. Michael Poulter and others in Vancouver, BC while a guest researcher at the National Research Council, Ottawa, ON. Moving from research, Dr. Mahan served three administrations as Director of Biosciences for the State of Maryland's biopharmaceutical industry, undertaking global business development initiatives, creating entrepreneurial assistance programs and providing diligence oversight for bioscience investments by the State's public venture fund. In addition, he later served as Director of Innovation and Business Development for Children's National Medical Center and its newly formed $150M Institute for Pediatric Surgical Innovation and Children's Research Institute to identify and accelerate promising research programs for commercialization and expand Children's intellectual property portfolio. Dr. Mahan joined OB Pharmaceuticals advisory board in 2016.

LONDON, ONTARIO January 2, 2018 -- Dr. Larry Mahan attended BioTech Showcase 2018 during JP Morgan week in San Francisco on behalf of OB Pharmaceuticals for 3 days of business partnering and a corporate presentation on the remarkable preclinical progress of the company's program on the development of oxynytones, novel molecules showing promise for the treatment and prevention of epilepsy and other related seizure disorders. More than twenty meetings transpired spanning business partnering and potential venture investment.

About BioTech Showcase
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its tenth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. In addition to biopharmaceutical and life science company executives, Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.

LONDON, ONTARIO March 10, 2017 -- Representatives from OB Pharmaceuticals attended BioEurope Spring 2017 in Barcelona, Spain, March 20-22 to meet with potential pharma and venture partners to expand development of its promising novel molecules for the treatment and prevention of epilepsy and other related seizure disorders.

About BioEurope Spring
With a focus on European innovation and global collaboration, BIO-Europe Spring is the premier springtime partnering conference from biotech, pharma and finance in the most innovative biopharma clusters in Europe. BIO-Europe Spring attracts a wide range of business leaders, including senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors and other industry experts.